The dataset used in this research was retrieved specifically for this study from the Chinese National HIV/AIDS Comprehensive Response Information Management System that contains routine HIV care data. Data are available upon request from the Institutional Review Board of the National Center of AIDS/STD Control and Prevention (NCAIDS) or the Board of Directors of NCAIDS. Applications should be submitted to Ms. Mengchi Liu at <mengchi@chinaaids.cn>, Research Administration Officer, Office of Directors, NCAIDS.

Introduction {#sec005}
============

Substantial evidence supports a strong link between HIV infection and increased incidence of a broad spectrum of malignancies. In the early 1980s, the US Centers for Disease Control and Prevention (CDC) identified Kaposi sarcoma (KS), non-Hodgkin lymphoma (NHL), and invasive cervical cancer (ICC) as AIDS-defining cancers (ADCs). Diagnosis of any one ADC marks progression to AIDS \[[@pone.0219766.ref001]\]. Prior to the introduction of antiretroviral therapy (ART) in the mid-1990s, incidence of ADCs among people living with HIV (PLHIV) was substantially elevated over that of the general population. However, since the widespread scale up of ART, cancer types/sites observed among PLHIV appears to have changed---incidence of KS and NHL has fallen dramatically, while incidence of non-AIDS-defining cancers (NADCs) has risen \[[@pone.0219766.ref002]--[@pone.0219766.ref007]\].

In general, NADCs can be categorized by their infectious versus non-infectious etiologies. A range of anogenital cancers and head and neck cancers, as well as some non-melanoma skin cancers are associated with the oncogenic subtypes of Human Papillomavirus (HPV). Epstein-Barr Virus (EBV), and in some cases, Human Herpesvirus 8 (HHV-8, the virus that causes KS), is involved in many of the nine different subtypes of lymphomas, while Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) are associated with liver cancer \[[@pone.0219766.ref003],[@pone.0219766.ref008]\]. Not surprisingly, PLHIV are known to be more susceptible to infection with these oncogenic viruses, and immunodeficiency may also interact with the oncogenesis. However, PLHIV are also known to have higher rates of exposure to cigarette smoke and alcohol, two of the top non-infectious carcinogens, which may also partially explain the higher rates of not only lung and liver cancers among PLHIV, but also cancers of the head and neck and cervix. Although the rise in NADCs may simply be a consequence PLHIV having increased longevity in the ART era, there is evidence suggesting that there are other factors at play. Compared to the general population, PLHIV are more often diagnosed at earlier ages with more aggressive cancers that have already progressed to later stages \[[@pone.0219766.ref003],[@pone.0219766.ref009]\].

Most cancer research has been performed among PLHIV of European or African heritage \[[@pone.0219766.ref005]--[@pone.0219766.ref007],[@pone.0219766.ref010]--[@pone.0219766.ref026]\]. Previous studies in Chinese populations (two hospital-based studies in Mainland China, with 3,554 and 1,946 patients, respectively, and one registry-based study with 15,269 patients in Taiwan) reported that the risk of KS, NHL, cervical, liver, and anal cancers were elevated among PLHIV compared to the general population \[[@pone.0219766.ref027]--[@pone.0219766.ref029]\]. However, the spectrum of malignancies observed among China's rapidly growing population of PLHIV has not yet been systematically described. Furthermore, the cancer spectrum in the general Chinese population differs from many developed countries. For instance, China has a higher incidence of liver, esophagus, nasopharynx, stomach, and lung cancers \[[@pone.0219766.ref030]\]. It is also not clear whether such differences in cancer spectra exist between PLHIV in China, and PLHIV in other countries.

Thus, we conducted a nationwide follow-up study using data from China's National HIV/AIDS Surveillance Program and National Free ART Program (NFATP) to retrospectively investigate the spectrum of malignancies among adult PLHIV in China.

Materials and methods {#sec006}
=====================

Study design {#sec007}
------------

We conducted a nationwide follow-up study to examine the spectrum of malignancies among Chinese adult PLHIV. To do this, we used routinely collected data for PLHIV who had been diagnosed with HIV infection on or before 31 December 2011 and were still alive and in care as of 1 January 2008. All participants contributed observed time from 1 January 2008 (i.e., the study start date) to 30 June 2012 (i.e., the study end date) and cancer cases were identified during this follow-up time.

Setting and data source {#sec008}
-----------------------

The data used for this study were collected during the normal operation of China's HIV/AIDS Surveillance System and NFATP. All data related to China's HIV response efforts are collected and maintained in a real-time, web-based repository called the HIV/AIDS Comprehensive Response Information Management System (CRIMS), which has been described elsewhere \[[@pone.0219766.ref031]\]. In brief, CRIMS contains records for all individuals diagnosed with HIV in China, and these records include contact and demographic information, testing and baseline clinical information, dates and details of all follow-up visits, and ART regimens and related assessments, as well as other health-related information (co-infections, co-morbidities) and dates and causes of death. After a diagnosis of HIV infection, but prior to the initiation of ART, PLWH are followed up once every 6 months. After ART initiation, patients are followed up 4 times in the first 3 months, and once every 3 months thereafter.

Eligibility criteria {#sec009}
--------------------

Study inclusion criteria were: 1) being ≥15 years of age, and 2) having been diagnosed with HIV on or before 31 December 2011. All patient records in CRIMS meeting these study inclusion criteria were extracted and then screened against exclusion criteria. Study exclusion criteria were: 1) having died or been lost to follow-up prior to the start of the study on 1 January 2008, or 2) not having attended at least one follow-up visit prior to 30 June 2012, the date all data were extracted. All remaining patients were included in the analysis.

Case identification {#sec010}
-------------------

Cancer cases were identified using reports of AIDS-related complications or causes of death at each follow-up visit. We categorized cancer cases based on the International Classification of Disease for Oncology, 3rd Edition (ICD-O-3) \[[@pone.0219766.ref032]\]. However, because approximately half of lymphoma records were not specified as to their type, we combined all cases of NHL, Hodgkin lymphoma (HL), and all other lymphomas together into a single category. This group was treated as a single cancer type in all analyses.

Observed time {#sec011}
-------------

The start of observed time was defined as either the study start date, 1 January 2008 (for those already diagnosed with HIV), or the date of HIV diagnosis, whichever was later. The inferred date of cancer incidence was defined as the median date between the date of cancer diagnosis and the date of the previous follow-up visit. Participants with inferred date of cancer incidence after the end of the study, 31 December 2011, were treated as cancer-free during the study period. For cancer-free individuals, the end of follow-up was defined as either 1) the date of last follow-up for those who were lost to follow-up, 2) the date of death, or 3) the end of the study for those who were still living. Observed time was calculated as the difference between first and last observation, expressed in person-years (PY).

Statistical analysis {#sec012}
--------------------

Characteristics of participants were presented as number and percent. Sex-specific cancer incidences were calculated for each malignancy site/type, and age-standardized incidence rates (ASIR) and standardized incidence ratios (SIR), along with their 95% confidence intervals (CIs) were calculated. Direct standardization was used to calculate ASIR. Two different standard populations were used: ASIR-China (ASIRC) was calculated using China's 2010 census data \[[@pone.0219766.ref033]\], and ASIR-world (ASIRW) was calculated using the World Health Organization (WHO) standard world population for 2002 to 2025 \[[@pone.0219766.ref034]\]. ASIRC and ASIRW were expressed per 100,000 PY. SIR was obtained by dividing the numbers of observed cases (numerator) by the expected numbers of cases (denominator). Expected cancer frequencies were determined using the observed sex- and 5-year, age-specific incidence rates from China's National Cancer Registry in 2008 \[[@pone.0219766.ref035]\]. All CIs presented were calculated assuming a Poisson distribution. SAS software version 9.3 (SAS Institute Inc., USA) was used for all analyses.

Ethical considerations {#sec013}
----------------------

This study was approved by the Institutional Review Board of the National Center for AIDS/STD Control and Prevention, China CDC, and by the Institutional Review Board of the University of California, Los Angeles. No informed consent was sought since all individuals diagnosed with HIV in China sign informed consent at the time of their initial entry into CRIMS, which includes the future use of their data for epidemiological study. All records, once extracted, were de-identified to ensure confidentiality.

Results {#sec014}
=======

Records of a total of 444,712 patients who met inclusion criteria were extracted. A total of 45,261 (10.2%) were excluded and therefore, 399,451 (89.8%) patients were included in the analysis and contributed a total of 813,238.9 PY of observed time.

As shown in [Table 1](#pone.0219766.t001){ref-type="table"}, a majority were 30--44 years of age (49.3%), male (69.8%), and Han Chinese (67.9%), and most had a junior high school-level education or less (74.3%). The most common HIV transmission route reported by participants was heterosexual contact (43.5%), followed by injecting drug use (27.3%), and blood product receipt or donation (10.2%). At the time of diagnosis, 62.0% of participants had not yet progressed to AIDS, while 38% had, and baseline CD4 counts were low---25.6% had ≥350 cells/mm^3^, 22.1% had 200--399 cells/mm^3^, and 27.2% had \<200 cells/mm^3^.

10.1371/journal.pone.0219766.t001

###### Characteristics of participants---Adults diagnosed with HIV infection prior to January 1, 2012, yet still alive and being followed prior to January 1, 2008.

![](pone.0219766.t001){#pone.0219766.t001g}

  ---------------------------------------------------------------------------------------------------------------------
  Baseline Characteristics                                                    Participants\       Observed Time\
                                                                              N (%)               PY (%)
  --------------------------------------------------------------------------- ------------------- ---------------------
  **Overall**                                                                 **399,451 (100)**   **813,238.9 (100)**

  **Age at HIV diagnosis, years**[^**a**^](#t001fn002){ref-type="table-fn"}                       

      15--29                                                                  116,082 (29.1)      213,789.8 (26.3)

      30--44                                                                  196,848 (49.3)      440,565.2 (54.2)

      45--59                                                                  60,917 (15.3)       124,932.1 (15.4)

      ≥60                                                                     25,604 (6.4)        33,951.8 (4.2)

  **Gender**                                                                                      

      Male                                                                    278,908 (69.8)      550,228.6 (67.7)

      Female                                                                  120,543 (30.2)      263,010.3 (32.3)

  **Ethnicity**                                                                                   

      Han Chinese                                                             271,375 (67.9)      557,772.6 (68.6)

      Other                                                                   128,076 (32.1)      255,466.4 (31.4)

  **Education Level**                                                                             

      Illiterate                                                              37,577 (9.4)        75,273.2 (9.3)

      Primary school                                                          112,932 (28.3)      232,735.9 (28.6)

      Junior high school                                                      146,270 (36.6)      303,861.8 (37.4)

      High school                                                             41,180 (10.3)       74,439.9 (9.2)

      ≥College                                                                22,881 (5.7)        36,115.5 (4.4)

      Missing                                                                 38,611 (9.7)        90,812.7 (11.2)

  **HIV Transmission Route**                                                                      

      Heterosexual contact                                                    173,853 (43.5)      290,022.6 (35.7)

      Injecting drug use                                                      108,911 (27.3)      259,168.0 (31.9)

      Blood product receipt or donation                                       40,860 (10.2)       128,043.6 (15.7)

      Homosexual contact                                                      29,169 (7.3)        40,022.4 (4.9)

      Sexual contact and injecting drug use                                   4,900 (1.2)         10,179.8 (1.3)

      Other/Unknown/Missing                                                   41,758 (10.5)       85,802.6 (10.6)

  **Disease Stage at Diagnosis**                                                                  

      HIV-infection                                                           247,625 (62.0)      445,270.7 (54.8)

      AIDS                                                                    151,826 (38.0)      367,968.3 (45.2)

  **CD4 Count (cells/mm**^**3**^**)**                                                             

      \<200                                                                   108,585 (27.2)      210,185.4 (25.8)

      200--349                                                                88,439 (22.1)       196,043.6 (24.1)

      ≥350                                                                    102,305 (25.6)      250,856.9 (30.8)

      Missing                                                                 100,122 (25.1)      156,153.1 (19.2)
  ---------------------------------------------------------------------------------------------------------------------

PY: person-years

^a^According to the National Bureau of Statistics of China \[[@pone.0219766.ref033]\], the age distribution of the general population in 2010 was: 16.6% ≤14 years of age, 74.5% 15--64 years of age, and 8.9% ≥65 years of age

As shown in [Table 2](#pone.0219766.t002){ref-type="table"}, 3,819 cancer cases were identified---2,808 among males, and 1,011 among females. The 5 most prevalent malignancies among males were lung cancer (n = 713), liver cancer (n = 539), lymphoma (n = 299), brain and central nervous system (CNS) cancers (n = 216), and stomach cancer (n = 137), and among females were lung cancer (n = 140), cervical cancer (n = 128), lymphoma (n = 117), brain and CNS cancers (n = 105), and liver cancer (n = 84).

10.1371/journal.pone.0219766.t002

###### Gender-stratified frequencies of malignancies and age-standardized incidence rates weighted for China (ASIRC) and for the world (ASIRW), 2008 to 2011.
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  Malignancy Site/Type (ICD-O-3 Code)                                                          Males, per 100,000   Females, per 100,000                                                                         
  -------------------------------------------------------------------------------------------- -------------------- -------------------------- -------------------------- ----------- -------------------------- --------------------------
  **All Cancers**                                                                              **2,808**            **776.4 (742.1--810.6)**   **881.7 (839.6--923.7)**   **1,011**   **486.5 (436.4--536.6)**   **508.9 (454.0--563.7)**
      All (Excluding Ill-defined/Unspecified)                                                  2,524                691.8 (659.7--724.0)       782.7 (743.3--822.0)       898         427.4 (380.5--474.2)       446.0 (394.7--497.3)
      Ill-defined/Unspecified                                                                  284                  84.6 (72.8--96.3)          99.0 (84.2--113.9)         113         59.2 (41.5--76.8)          62.8 (43.5--82.1)
  **AIDS-Defining Cancers (all lymphomas**[^**c**^](#t002fn004){ref-type="table-fn"}**)**                                                                                                                        
      Kaposi sarcoma (9140)                                                                    132                  23.9 (18.9--28.8)          23.9 (18.5--29.2)          39          14.2 (9.0--19.4)           13.9 (8.5--19.2)
      Lymphoma^c^ (959, 965)                                                                   299                  63.1 (54.6--71.7)          65.8 (56.3--75.4)          117         48.0 (32.7--63.2)          48.8 (32.3--65.2)
      Cervical (C53)                                                                           \-                   \-                         \-                         128         47.6 (38.3--57.0)          48.0 (38.3--57.8)
  **Non-AIDS-Defining Cancers (no lymphomas**[^**c**^](#t002fn004){ref-type="table-fn"}**)**                                                                                                                     
      Oral cavity (C00--C09)                                                                   13                   5.3 (2.1--8.4)             6.6 (2.3--10.8)            4           1.9 (0.0--3.9)             2.0 (0.0--4.2)
      Nasopharynx (C11)                                                                        38                   11.0 (7.1--15.0)           12.0 (7.6--16.3)           9           3.8 (1.1--6.6)             4.3 (1.1--7.4)
      Other head and neck (C12--C14, C30--C32)                                                 47                   13.8 (9.1--18.6)           15.9 (10.0--21.7)          17          7.6 (3.3--11.8)            8.0 (3.4--12.7)
      Esophagus (C15)                                                                          78                   25.3 (19.0--31.7)          29.0 (21.4--36.7)          19          14.8 (1.8--27.9)           16.1 (1.7--30.4)
      Stomach (C16)                                                                            137                  44.1 (35.6--52.6)          52.6 (41.6--63.5)          60          47.8 (24.2--71.4)          51.4 (25.5--77.3)
      Colon and rectum (C18--20)                                                               121                  34.4 (27.3--41.5)          39.2 (30.5--47.9)          32          22.0 (11.0--33.0)          23.1 (11.3--34.8)
      Anus (C21)                                                                               2                    0.2 (0.0--0.5)             0.2 (0.0--0.4)             0           \-                         \-
      Liver (C22)                                                                              539                  145.7 (131.0--160.3)       160.8 (143.6--178.0)       84          39.2 (27.4--51.0)          41.4 (28.7--54.2)
      Other digestive system (C23, C24, C26)                                                   6                    1.8 (0.2--3.4)             2.6 (0.0--5.3)             1           0.7 (0.0--2.2)             0.9 (0.0--2.6)
      Pancreas (C25)                                                                           41                   12.0 (7.8--16.3)           14.2 (8.8--19.5)           2           5.0 (0.0--14.3)            6.4 (0.0--18.6)
      Lung (C34)                                                                               713                  226.0 (206.7--245.4)       266.3 (241.8--290.8)       140         66.8 (52.5--81.1)          71.3 (55.7--86.9)
      Mediastinum and pleura (C38)                                                             4                    0.7 (0.0--1.5)             0.7 (0.0--1.5)             2           0.5 (0.0--1.3)             0.5 (0.0--1.1)
      Bone (C40)                                                                               11                   4.2 (1.3--7.0)             5.3 (1.4--9.2)             2           0.9 (0.0--2.1)             1.0 (0.0--2.5)
      Skin (C44)                                                                               17                   4.6 (2.1--7.2)             5.0 (2.2--7.9)             9           3.2 (1.0--5.3)             3.2 (1.0--5.5)
      Soft tissue (C47--C49)                                                                   5                    1.1 (0.0--2.3)             1.1 (0.0--2.5)             7           2.1 (0.5--3.7)             2.1 (0.5--3.7)
      Breast (C50)                                                                             2                    0.3 (0.0--0.8)             0.3 (0.0--0.8)             31          13.6 (7.0--20.2)           14.1 (7.1--21.2)
      Vagina and vulva (C51, C52)                                                              \-                   \-                         \-                         2           0.7 (0.0--1.7)             0.7 (0.0--1.8)
      Corpus uteri (C54)                                                                       \-                   \-                         \-                         48          24.9 (10.8--39.0)          26.2 (10.9--41.6)
      Ovary and other female genital tissue (C55--C58)                                         \-                   \-                         \-                         5           1.7 (0.2--3.1)             1.7 (0.1--3.4)
      Penis (C60)                                                                              6                    2.1 (0.2--3.9)             2.4 (0.3--4.5)             \-          \-                         \-
      Prostate (C61)                                                                           9                    4.3 (1.3--7.3)             6.1 (1.7--10.5)            \-          \-                         \-
      Other male genital (C62, C63)                                                            5                    1.1 (0.0--2.5)             1.2 (0.0--2.6)             \-          \-                         \-
      Kidney (C64)                                                                             10                   2.5 (0.5--4.5)             2.9 (0.4--5.3)             2           0.6 (0.0--1.5)             0.6 (0.0--1.5)
      Other urinary system (C65--C68)                                                          3                    0.8 (0.0--1.8)             0.9 (0.0--2.0)             0           \-                         \-
      Bladder (C67)                                                                            9                    3.8 (1.1--6.6)             5.6 (1.2--9.9)             1           0.7 (0.0--2.2)             0.9 (0.0--2.6)
      Eye (C69)                                                                                4                    1.1 (0.0--2.4)             1.1 (0.0--2.6)             3           1.1 (0.0--2.5)             1.2 (0.0--2.6)
      Brain and CNS (C70, C71)                                                                 216                  45.5 (38.2--52.8)          47.4 (39.2--55.6)          105         43.0 (28.5--57.6)          43.0 (27.3--58.7)
      Thyroid (C73)                                                                            2                    0.4 (0.0--1.0)             0.4 (0.0--1.0)             0           \-                         \-
      Multiple myeloma (C90)                                                                   4                    2.0 (0.0--4.0)             2.3 (0.0--4.6)             1           0.4 (0.0--1.3)             0.5 (0.0--1.6)
      Melanoma (872)                                                                           1                    0.3 (0.0--0.9)             0.4 (0.0--1.1)             0           \-                         \-
      Leukemia (981)                                                                           50                   10.3 (6.8--13.8)           10.7 (6.7--14.6)           28          14.4 (6.1--22.6)           14.6 (5.9--23.4)

ICD-O-3: International Classification of Disease for Oncology \[[@pone.0219766.ref032]\], 3rd Edition, ASIRC: age-standardized incidence rate for China, ASIRW: age-standardized incidence rate for the world, CI: 95% confidence interval, CNS: central nervous system

^a^ASIRC is per 100,000, weighted by Chinese population in 2010 according to national census data \[[@pone.0219766.ref033]\], and CI calculated based on an assumed Poisson distribution

^b^ASIRW is per 100,000, weighted by the World Health Organization's world standard population data for 2002 to 2025 \[[@pone.0219766.ref034]\], and CI calculated based on an assumed Poisson distribution

^c^Because approximately half of lymphoma records did not specify Hodgkin or Non-Hodgkin lymphoma, combined observed and expected lymphoma figures were calculated

[Table 2](#pone.0219766.t002){ref-type="table"} also presents sex-specific ASIRC and ASIRW results overall and by malignancy site/type. Overall ASIRC was 776.4 per 100,000 (742.1--810.6) for males and 486.5 per 100,000 (436.4--536.6) for females. Excluding cancer cases with ill-defined or unspecified primary sites/types, overall ASIRC was 691.8 per 100,000 (659.7--724.0) for males and 427.4 per 100,000 (380.5--474.2) for females. Overall ASIRW was 881.7 per 100,000 (839.6--923.7) for males and 508.9 per 100,000 (454.0--563.7) for females, higher compared to ASIRC. ASIRW was also higher than ASIRC for both males and females when malignancies that were ill-defined/unspecified were excluded.

ASIRW values were similar or greater than ASIRC values for all specific malignancy sites/types for both males and females. Lung cancer had the highest ASIRC among males at 226.0 per 100,000 (206.7--245.4) followed by liver cancer at 145.7 per 100,000 (131.0--160.3) and lymphoma at 63.1 per 100,000 (54.6--71.7). Lung cancer also had the highest ASIRC among females at 66.8 per 100,000 (52.5--81.1) followed by lymphoma at 48.0 per 100,000 (32.7--63.2), stomach cancer at 47.8 per 100,000 (42.2--71.4), and cervical cancer at 47.6 per 100,000 (38.3--57.0).

[Table 3](#pone.0219766.t003){ref-type="table"} displays results of sex-specific SIR calculations overall and by malignancy site/type. Overall SIR was 3.4 (3.3--3.5) for males and 2.6 (2.4--2.7) for females. After excluding ill-defined or unspecified malignancies, SIR for males was 3.1 (3.0--3.2) and for females was 2.3 (2.2--2.5). Highest SIR was observed for KS at 2,639.8 (2,208.7--3,130.5) among males, and 1,593.5 (1,133.0--2,178.4) among females, and lymphomas (all types) was 13.9 (12.3--15.5) among males and 16.0 (13.2--19.1) among females. Among males, high SIR was observed for cancers of the eye (10.3 \[2.8--26.4\]), brain and CNS (8.2 \[7.1--9.3\]), lung (4.8 \[4.4--5.1\]), and liver (3.9 \[3.6--4.2\]). Among females, high SIR was found for other head and neck cancers (16.0 \[9.3--25.6\]), and cancers of the eye (9.6 \[1.9--28.1\]), brain and CNS (8.8 \[7.2--10.7\]), lung (4.2 \[3.5--5.0\]), and liver (4.0 \[1.8--8.0\]). ICC had an SIR of 3.8 (3.2--4.6).

10.1371/journal.pone.0219766.t003

###### Gender-stratified frequencies of malignancies and standard incidence ratios (SIR) for China, 2008 to 2011.
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  Malignancy Site/Type (ICD-O-3 Code)                                                          Males       Females                                                          
  -------------------------------------------------------------------------------------------- ----------- ----------- ---------------------------- ----------- ----------- ----------------------------
  **All Cancers**                                                                              **2,808**   **832.2**   **3.4 (3.3--3.5)**           **1,011**   **392.6**   **2.6 (2.4--2.7)**
      All (Excluding Ill-defined/Unspecified)                                                  2,524       809.9       3.1 (3.0--3.2)               898         382.2       2.3 (2.2--2.5)
      Ill--defined/Unspecified                                                                 284         22.3        12.8 (11.3--14.3)            113         10.4        10.9 (9.0--13.1)
  **AIDS-Defining Cancers (all lymphomas**[^**b**^](#t003fn003){ref-type="table-fn"}**)**      **431**     **21.6**    **19.9 (18.1--21.9)**        **284**     **40.7**    **7.0 (6.2--7.8)**
      Kaposi sarcoma (9140)                                                                    132         0.05        2,639.8 (2,208.7--3,130.5)   39          0.02        1,593.5 (1,133.0--2,178.4)
      Lymphoma[^**b**^](#t003fn003){ref-type="table-fn"} (959, 965)                            299         21.6        13.9 (12.3--15.5)            117         7.3         16.0 (13.2--19.1)
      Cervical (C53)                                                                           \-          \-          \-                           128         33.4        3.8 (3.2--4.6)
  **Non-AIDS-Defining Cancers (no lymphomas**[^**b**^](#t003fn003){ref-type="table-fn"}**)**   **2,377**   **810.6**   **2.9 (2.8--3.1)**           **727**     **351.9**   **2.1 (1.9--2.2)**
      Oral cavity (C00--C09)                                                                   13          9.9         1.3 (0.7--2.2)               4           3.3         1.2 (0.3--3.1)
      Nasopharynx (C11)                                                                        38          22.9        1.7 (1.2--2.3)               9           5.2         1.7 (0.8--3.3)
      Other head and neck (C12--C14, C30--C32)                                                 47          13.6        3.4 (2.5--4.6)               17          1.1         16.0 (9.3--25.6)
      Esophagus (C15)                                                                          78          62.5        1.2 (1.0--1.6)               19          10.9        1.7 (1.0--2.7)
      Stomach (C16)                                                                            137         116.1       1.2 (1.0--1.4)               60          26.7        2.2 (1.7--2.9)
      Colon and rectum (C18--C20)                                                              121         81.5        1.5 (1.2--1.8)               32          29.5        1.1 (0.7--1.5)
      Anus (C21)                                                                               2           0.7         2.9 (0.3--10.5)              0           0.2         0.0 (0.0--19.7)
      Liver (C22)                                                                              539         138.3       3.9 (3.6--4.2)               84          16.1        5.2 (4.2--6.5)
      Other digestive system (C23, C24, C26)                                                   6           12.1        0.5 (0.2--1.1)               1           5.3         0.2 (0.0--1.0)
      Pancreas (C25)                                                                           41          19.7        2.1 (1.5--2.8)               2           6.1         0.3 (0.0--1.2)
      Lung (C34)                                                                               713         150.1       4.8 (4.4--5.1)               140         33.2        4.2 (3.5--5.0)
      Mediastinum and pleura (C38)                                                             4           4.9         0.8 (0.2--2.1)               2           1.3         1.5 (0.2--5.5)
      Bone (C40)                                                                               11          7.0         1.6 (0.8--2.8)               2           2.5         0.8 (0.1--2.8)
      Skin (C44)                                                                               17          7.5         2.3 (1.3--3.6)               9           2.2         4.0 (1.8--7.7)
      Soft tissue (C47--C49)                                                                   5           4.5         1.1 (0.4--2.6)               7           1.8         3.9 (1.5--8.0)
      Breast (C50)                                                                             2           1.2         1.6 (0.2--5.8)               31          98.8        0.3 (0.2--0.4)
      Vagina and vulva (C51, C52)                                                              \-          \-          \-                           2           0.9         2.2 (0.2--8.0)
      Corpus uteri (C54)                                                                       \-          \-          \-                           48          17.4        2.8 (2.0--3.7)
      Ovary and other female genital tissue (C55--C58)                                         \-          \-          \-                           5           18.0        0.3 (0.1--0.6)
      Penis (C60)                                                                              6           2.2         2.8 (1.0--6.1)               \-          \-          \-
      Prostate (C61)                                                                           9           14.8        0.6 (0.3--1.2)               \-          \-          \-
      Other male genital tissue (C62, C63)                                                     5           5.0         1.0 (0.3--2.4)               \-          \-          \-
      Kidney (C64)                                                                             10          20.6        0.5 (0.2--0.9)               2           5.2         0.4 (0.0--1.4)
      Other urinary system (C65--C68)                                                          3           2.7         1.1 (0.2--3.3)               0           1.0         0.0 (0.0--3.5)
      Bladder (C67)                                                                            9           24.0        0.4 (0.2--0.7)               1           2.9         0.4 (0.0--1.9)
      Eye (C69)                                                                                4           0.4         10.3 (2.8--26.4)             3           0.3         9.6 (1.9--28.1)
      Brain and CNS (C70, C71)                                                                 216         26.4        8.2 (7.1--9.3)               105         11.9        8.8 (7.2--10.7)
      Thyroid (C73)                                                                            2           17.3        0.1 (0.0--0.4)               0           28.8        0.0 (0.0--0.1)
      Multiple myeloma (C90)                                                                   4           3.8         1.1 (0.3--2.7)               1           1.3         0.8 (0.0--4.3)
      Melanoma (872)                                                                           1           1.6         0.6 (0.0--3.6)               0           0.7         0.0 (0.0--5.2)
      Leukemia (981)                                                                           50          17.2        2.9 (2.2--3.8)               28          8.8         3.2 (2.1--4.6)

ICD-O-3: International Classification of Disease for Oncology \[[@pone.0219766.ref032]\], 3rd Edition, SIR: standard incidence ratio, CI: 95% confidence interval, CNS: central nervous system

^a^SIR is calculated using Chinese National Cancer Registry data for 2008 (Expected) \[[@pone.0219766.ref035]\], and CI calculated based on an assumed Poisson distribution

^b^Because approximately half of lymphoma records did not specify Hodgkin or Non-Hodgkin lymphoma, combined observed and expected lymphoma figures were calculated

Discussion {#sec015}
==========

We observed higher incidence of cancer among Chinese adults with HIV, compared to the general Chinese population. As expected, both the incidence of ADC and NADC were higher. These findings are supported by three previous studies in ethnic Chinese populations: Zhang et al. (Hubei Province, 2004--2008) \[[@pone.0219766.ref027]\], Yang et al. (Beijing Municipality, 2008--2013) \[[@pone.0219766.ref028]\], and Chen et al. (Taiwan, 1998--2009) \[[@pone.0219766.ref029]\]. However, the finding of many NADCs at higher incidence rates than ADCs was somewhat of a surprise, given that ART coverage in China during the study period was \<50% \[[@pone.0219766.ref036]\]. Further comparison of the cancer spectrum between PLHIV in different populations indicates that both infectious and non-infectious etiologies may play important roles in oncogenesis in the HIV-infected population in China.

HHV-8 Infection {#sec016}
---------------

KS is well-known to be caused by HHV-8, and PLHIV are commonly infected with HHV-8. In the pre-ART era, KS incidence was observed to be up to 2,000-fold greater among PLHIV, and the more severe the immunodeficiency, the higher the likelihood of KS occurrence \[[@pone.0219766.ref008]\]. In our study, 171 cases of KS were observed, which represented only 4.5% of all cancer cases observed. Not surprisingly, KS SIR was high---2,639.8 among males and 1,593.5 among females---as KS in the absence of HIV is very rare in Mainland China. However, the ASIRC of KS (23.9 per 100,000 for males and 14.2 per 100,000 for females) was lower than in the Taiwan study \[[@pone.0219766.ref029]\], and in many previous studies in the United States, Europe and sub-Saharan Africa \[[@pone.0219766.ref005]--[@pone.0219766.ref007],[@pone.0219766.ref010]--[@pone.0219766.ref026],[@pone.0219766.ref037]\]. The low prevalence of HHV-8 infection in Mainland China may be one cause of lower KS incidence rate \[[@pone.0219766.ref038],[@pone.0219766.ref039]\]. Previous studies have shown that the incidence rate and SIR of KS has dropped dramatically since the introduction of ART \[[@pone.0219766.ref005],[@pone.0219766.ref012],[@pone.0219766.ref018],[@pone.0219766.ref021]\], and we expect a similar trend to develop in China, since ART coverage is still expanding under the NFATP as China strives to meet the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 Targets \[[@pone.0219766.ref040],[@pone.0219766.ref041]\].

EBV Infection {#sec017}
-------------

EBV infection is known to be associated with several forms of lymphomas, especially NHL and HL, and increased incidence of NHL has been documented among those with more serious immunodeficiency. China's general population is known to have a high prevalence of EBV infection---one recent study found EBV prevalence among Chinese children to be 50% by age 3 and 90% by age 8 \[[@pone.0219766.ref042]\]. Both Zhang et al. and Chen et al. found that NHL was the most commonly observed malignancy \[[@pone.0219766.ref027],[@pone.0219766.ref029]\], and Chen et al. found NHL incidence of 329 per 100,000 (SIR 23.7) for males and 256 per 100,000 (SIR 22.4) for females, whereas incidence of HL was 18 per 100,000 (SIR 9.4) for males and 14 per 100,000 (SIR 7.8) for females \[[@pone.0219766.ref029]\]. However, limitations in the data we collected meant we were only able to report incidence for all lymphomas as a group---SIR of 13.9 for males, 16.0 for females, and ASIRC of 63.1 per 100,000 among males and 48.0 per 100,000 among females, consistent with previous studies of NHL in the post-ART era \[[@pone.0219766.ref007],[@pone.0219766.ref012],[@pone.0219766.ref018],[@pone.0219766.ref026]\].

HPV Infection {#sec018}
-------------

A broad range of cancers, mostly affecting the anogenital and head and neck areas, are known to be caused by infection with one or more of the high-risk subtypes of HPV \[[@pone.0219766.ref043]\]. Female PLHIV in China have a high prevalence of HPV co-infection. In one recent study, prevalence of carcinogenic HPV infection among women with HIV was nearly 40% \[[@pone.0219766.ref044]\]. ICC is a major health problem in China, causing the deaths of approximately 40,000 women annually. We observed 128 cases of ICC in our cohort, for an ASIRC of 47.6 per 100,000 and SIR of 3.8, consistent with previous studies in which females with HIV were estimated to be roughly 5 times more likely to develop ICC \[[@pone.0219766.ref020],[@pone.0219766.ref021],[@pone.0219766.ref023],[@pone.0219766.ref024]\]. Zhang et al. found a higher SIR of 68.1, and all 14 cancer cases observed among women in the study were ICC \[[@pone.0219766.ref027]\]. However, in the Taiwan study, incidence of ICC was 413 per 100,000, with SIR at 14.0 \[[@pone.0219766.ref029]\].

HPV infection is also common among Chinese men who have sex with men (MSM). A recent study in three Chinese cities found high-risk subtype HPV infection among 51% of participants overall, and among 70% of participants with HIV infection \[[@pone.0219766.ref045]\]. HPV-associated anal cancer has risen to a steady high level among MSM globally \[[@pone.0219766.ref008]\]. However, very few cases of anal cancer among PLHIV in Mainland China had previously been reported. Zhang et al. found zero cases of anal cancer \[[@pone.0219766.ref027]\], Yang et al. found 3 among men \[[@pone.0219766.ref028]\], and we found only 2 (ASIRC: 0.2 per 100,000, SIR: 2.9). A possible explanation for the low incidence of anal cancer thus far observed among men with HIV infection in China is the relatively low prevalence of HIV among MSM during the study period. In our study, only 7.3% of participants reported acquiring HIV infection via homosexual contact. However, the rapid increase of HIV infection in recent years and a high prevalence of HPV infection among MSM in China predicts a rise in anal cancer cases in the future, which may approximate the incidence rate in the Taiwan cohort (45.3 per 100,000, SIR 18.5) \[[@pone.0219766.ref029]\].

HBV and HCV Infection {#sec019}
---------------------

HBV and HCV infection are associated with hepatocellular carcinoma, which accounts for \>90% liver cancers. Liver cancer is known to be more prevalent and have higher incidence in east and southeast Asia, with China alone having 50% of all new cases of liver cancer worldwide in 2012 \[[@pone.0219766.ref030]\]. Incidence of liver cancer is higher among those with HIV in the US and other European countries \[[@pone.0219766.ref005],[@pone.0219766.ref007],[@pone.0219766.ref011],[@pone.0219766.ref012],[@pone.0219766.ref017],[@pone.0219766.ref019],[@pone.0219766.ref023],[@pone.0219766.ref024]\]. In China, HIV/HCV co-infection is very common among former blood product donors and recipients as well as people who inject drugs (PWID) \[[@pone.0219766.ref046]\], and the prevalence of HBV/HIV and HCV/HIV co-infection, and HBV/HCV/HIV triple infection were 8.7%, 18.2%, and 3.3%, respectively, among PLHIV in China's NFATP \[[@pone.0219766.ref047]\]. As expected, a high SIR for liver cancer was found by Zhang et al. (6.0, male and female combined) \[[@pone.0219766.ref027]\], and 14 liver cancer cases were identified by Yang et al., which accounted for 9% of all malignancies observed \[[@pone.0219766.ref028]\]. In our study, liver cancer had a very high ASIRC among males, 145.7 per 100,000, similar to the Taiwan study (185 per 100,000) \[[@pone.0219766.ref029]\], and an SIR, 3.9 in males, 5.2 in females, similar to previous studies \[[@pone.0219766.ref005],[@pone.0219766.ref007],[@pone.0219766.ref011],[@pone.0219766.ref012],[@pone.0219766.ref017],[@pone.0219766.ref019],[@pone.0219766.ref023],[@pone.0219766.ref024]\].

Other infections may also impact incidence of cancers in PLHIV in China. For example, *Helicobacter pylori* has been associated with stomach cancer. Abovementioned HPV infection has also been associated with penile cancer, oral cavity cancers, other cancers of the head and neck, and non-melanoma skin cancers, and EBV infection has been linked to nasopharyngeal cancer.\[[@pone.0219766.ref008]\] Incidence rates of all these malignancies were elevated in our study with the one exception---stomach cancer among male PLHIV was not elevated, which is notable since China bears nearly half of the global burden of non-cardia gastric cancers \[[@pone.0219766.ref048]\].

Smoking {#sec020}
-------

Previous studies have found that tobacco smoking, as well as the incidence rate of lung cancer are higher among PLHIV than in the general population \[[@pone.0219766.ref003],[@pone.0219766.ref004],[@pone.0219766.ref019]\]. As anticipated, lung cancer incidence was very high in our study---ASIRC of 226.0 per 100,000 among males and 66.8 per 100,000 among females, and SIR of 4.8 for males and 4.2 for females. The incidence rate of lung cancer in our study was higher than the Taiwan cohort \[[@pone.0219766.ref029]\], which may be attributed to higher prevalence of tobacco smoking in males in Mainland China (53%) than in Taiwan (32--38%) \[[@pone.0219766.ref049],[@pone.0219766.ref050]\].

To the authors' knowledge the present study was the first ever nationwide investigation of the spectrum of malignancies among PLHIV in China and adds to a literature containing few such studies in middle-income country settings. The very large size and nationwide scope of our cohort were two important strengths of our study, which facilitated detection of cancers with low incidence and perhaps improved the overall accuracy of our incidence estimates.

Nevertheless, our study had several limitations. Firstly, only individuals who had been diagnosed with HIV infection could be included in our analysis, and cancer incidence rate in undiagnosed PLHIV remains unknown. Moreover, we could not evaluate cancer cases among the 10.2% of cases (45,261 of 444,712) that were excluded due to either death or loss to follow-up prior to the study's start or no record of follow-up during the study period. However, a near 90% inclusion rate suggests that our study population is indeed nationally representative. Secondly, because original pathology findings were not included in CRIMS records, their re-examination for accuracy of cancer diagnosis could not be performed. This resulted in some cancer cases lacking a specific diagnosis (classified in our study as ill-defined/unspecified) and likely others being misdiagnosed, both of which may have introduced some miss-classification bias that could have caused under- or over-estimation of some incidence calculations. An example of this may be found in the surprisingly high numbers of brain and CNS cancers observed in our study population. It is likely that some of these cases were, in fact, primary CNS lymphomas \[[@pone.0219766.ref051]\]. Similarly, it is likely that some cancer cases in our study population went undiagnosed. This too would have biased our results toward under-estimation of cancer incidences. Thirdly, due to the lack of specificity in nearly half of the lymphoma cases in the cohort, we had to classify all lymphomas together into a single group. This prevented comparison of ADC and NADC incidence within the current study and previous studies.

Conclusion {#sec021}
==========

The findings from this study provide strong evidence of a substantial cancer burden among adult PLHIV in China between 2008 and 2011. Although further study is clearly needed, these results suggest that China should expect that this burden has grown during the period 2012 to 2018, and will continue to do so, as it pushes to further scale up the NFATP in an attempt to meet the UNAIDS 90-90-90 Targets.\[[@pone.0219766.ref040],[@pone.0219766.ref041]\] Meeting these goals will undoubtedly result in an overall larger and older Chinese PLHIV population, which will require proactive and accurate cancer screening as well as specialized treatment and case management.

The authors would like to acknowledge all healthcare professionals who are working hard serving the needs of PLHIV in China, and to thank them for their contributions to national HIV/AIDS surveillance and national cancer registry system data collection.

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.
